LXRX Lexicon Pharmaceuticals Inc

$LXRX Honestly, there is no US equity out there has the explosive potential like Lexi. Not NVDA, not GOOG, not AAPL, not MSFT, not AMZN, not META, not TSM, not TSLA, not SPCX, not SKHY, not GLD, not SLV, and certainly not Crypto. A year ago, I could add CORT, but it went up from $30 to $110 already. IMHO, Lexi could jump to $3.50 within a year from the corremt $1.50, and be around $5.00 in 2027, i.e. 4x to 5x returns before EOY 2027. Then 2028 comes, it may continue it's upward movement to $7.50 facilitating a BO offer north of $15.00. I am not saying this because I own shares more than all the officers at LXRX except RD, but with a firm believe and conviction that multiple blockbuster drugs from Lexi are going to make an impact to improve patients' lives suffering from T1DM, HCM, NPDP and obesity affection billions i/around the be world.

$LXRX The wait is killing me. When is the $5 so that I can get the hell out of this stock and end the misery.

$LXRX it’s just a game. It’s a game of fear and impatience, and the strangedy to win at this game is don’t let the artificial slide convince you of something that’s the opposite just around the corner. Instead I would be using these opportunities to position myself for maximum gain and wait for the right time to sell, which is not now due to 4 big catalysts on the horizon. Don’t let them play you.

$LXRX I couldn't tell you when to add any better than when we see humble-bob and Woo_S both coming out to trash the stock. Now it is confirmed, and I added a few more shares of LXRX today using my monthly dividends from YYY. Thank you both so that I don't have to do my DD or read the charts.

$LXRX Horror just horror, i thought we won't go under 2$ again but this ticker always likes to disappoint.

$LXRX $LXRX Piper Sandler Drops Fresh $6.00 Target (+303% Upside) Post-Summit! 🏛️🎯🔥 While algorithms walked LXRX to $1.49 on low volume, Piper Sandler analyst Yasmeen Rahimi officially reaffirmed her BUY rating with a $6.00 price target this morning (Oct 26)! Why Wall Street Refuses to Sell: 1. +303% Upside vs. $1.49: Piper’s $6.00 and Cantor’s $8.00 targets show institutional analysts value LXRX at 4x to 5x today’s tape. 2. Cash Floor & $NVO Deal: $135.6M net cash ($0.30/sh) + $1.0B Novo Nordisk ($NVO) obesity deal ($2.25/sh) creates a hard floor of $2.55/sh (at 445M shares). At $1.49, you get cash & $NVO at a 42% discount! 3. Pipeline Valued at $0.00: The market gives zero credit to the Q4 2026 T1D oral pill (replacing insulin shots; beating legacy pills like empagliflozin from $LLY) or Phase 3 HCM (Q1 2027 data; BMS paid $13.1B for Camzyos)! 4. Nov 5 Earnings, news, updates, on T1 Submission and clarity on goalpoasts, guidance. The $1.49 tape is an obvious pricing disconnect.

$LXRX how much money have you lost in this stock? You sound pretty desperate, even by LXRX standards..

$LXRX We hit the 1.50 mark faster than I thought. I don't see any potential catalysts until Q1. The (hopefully) upcoming announcement of the Zynquista resubmission isn't likely to have much of an impact IMO. The FDA decision will be another story. I'm still long and bullish, but I also see us very likely testing support at 1.39 and pushing below that before we bounce. I'll put in my buy at 1.20. If I get it great. If we don't reach 1.20, that's great too. GL Longs. God willing in 2027 we'll all get paid.

$LXRX I still think that we are at the bottom here. I sure wish I had some dry powder, but unfortunately, I don’t! 😆 Doc C. 🤓

$LXRX it’s been 3 months downwards. I feel frustrated…. Any of you guys feel the same way?

$LXRX which will happen first in 2027? Disclosure of aliens on earth, or Lexicon hitting $4?

$LXRX Great news, if you are a mouse. A desperate announcement likely to try and stop the bleeding. This is not newsworthy in my view. More fuel for the shorts. Hey Exton, let’s hear about the Zynquista filing, a pilavapadin partnership and phase 3 trial date.

$LXRX RBC Capital Markets specifically attributed much of the recent biotech pullback to reduced acquisition activity combined with higher rates and risk aversion. It expects M&A to recover during the coming months. (Investor's Business Daily} 'But things are looking up for biotech stocks, says RBC's Abrahams. The lower valuations will undoubtedly make some companies more attractive as takeover candidates. Further, Big Pharma can ill afford to sit on the M&A sidelines. A patent cliff continues to threaten $300 billion to $400 billion in sales beginning in 2028, according to various estimates.'

$LXRX The controlling shareholder, thru Artal, Siren (Invus) and RD's personal holding, has very little interest in the daily SP actions. The 84% of the 445M outstandings are held by Tutes (including Artal and Siren), who are mostly invested in Lexi for the LT. If we take out the 51.75M shares held by RD from the remaining 16%, we end up with a little less than 20M shares held by retail investor, including most of the longs in the board. As of 9/30/26, the short interes in Lexi is 25.8M shares. So, you see, more than 25M shorties teaming up with MM can easily overwhelm us retail investors, who is only 20M strong, during this quiet period void of positive catalysts in this war of SP swings. It didn't help that ME advertised a mid-year Zynquista resubmission early in the year, but delay it to Q4. Nevertheless, Q4 is just around the corner; Q1 Inpefa/HCM readout is within sight; LX9851 P1 readout and P2 start in H1/27; and Pilavapadin partnership/P3 is in the working. GLTA and cheers!

$LXRX I’m ready for that PR of Zynquista NDA submission along with the DKA rates the data shows. Shorts will cover and squeeze this.

$LXRX What a joke. Can't even hold up 5 cents. Be lucky to close flat today. 1 month chart is so pathetic for a company with so many catalysts in play.

$LXRX My expectations of the upcoming LXRX Earnings Conference Call: + provide an update on their refiling of Zynquista. It doesn’t need to be filed but they should update the status of the refiling and the key data in the refiling (DKA incidence from the STENO trials, etc.). + Show the third $10 million milestone payment from Novo which will keep any operating losses minor. Their loan from Hercules, which paid off their existing loan, only requires interest payments + Hopefully mention LX9851 as Novo should pay a $60 million milestone payment which should be in the first half of 2027 which should pay for over half of LRXR typical annual operating expenses + Talk about how they should also start receiving royalties from VIatris for sales of Inpefa worldwide (ex-USA and EU). So, things are looking up for LXRX cash flow and Pilavapadin could rise up and get a partner and upfront payment but I expect this to just sit and get little Q&A

$LXRX D4mn it sucks to be right. Soon to be OTC and I lose what I risked. complete scam 90% of the companies in bio sector are... should not be allowed to be publicly traded.. This is DEAD.

$LXRX In the HCM mouse model, it improved cardiac function while reducing heart muscle thickening and fibrosis, with improved mitochondrial energy metabolism. In a separate study, sotagliflozin reduced platelet activation and thrombus formation without impairing normal hemostasis—effects not observed with empagliflozin. These findings highlight the potential advantages of dual SGLT1/SGLT2 inhibition.

$LXRX Will be hilarious when submittal is anounced. And short coverage takes us to 5 bucks+ hah hah hah ...